CN102933201B - 抗真菌药物组合物 - Google Patents

抗真菌药物组合物 Download PDF

Info

Publication number
CN102933201B
CN102933201B CN201180028753.8A CN201180028753A CN102933201B CN 102933201 B CN102933201 B CN 102933201B CN 201180028753 A CN201180028753 A CN 201180028753A CN 102933201 B CN102933201 B CN 102933201B
Authority
CN
China
Prior art keywords
pharmaceutical composition
general formula
concentration
quality
polyethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180028753.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN102933201A (zh
Inventor
久保田信雄
小林浩一
增田孝明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Original Assignee
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pola Pharma Inc, Nihon Nohyaku Co Ltd filed Critical Pola Pharma Inc
Publication of CN102933201A publication Critical patent/CN102933201A/zh
Application granted granted Critical
Publication of CN102933201B publication Critical patent/CN102933201B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201180028753.8A 2010-06-11 2011-06-10 抗真菌药物组合物 Active CN102933201B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2010148255 2010-06-11
JP2010-148255 2010-06-11
JP2010-181923 2010-07-30
JP2010181923 2010-07-30
PCT/JP2011/063860 WO2011155640A1 (en) 2010-06-11 2011-06-10 Antimycotic pharmaceutical composition

Publications (2)

Publication Number Publication Date
CN102933201A CN102933201A (zh) 2013-02-13
CN102933201B true CN102933201B (zh) 2015-12-16

Family

ID=44544289

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180028753.8A Active CN102933201B (zh) 2010-06-11 2011-06-10 抗真菌药物组合物

Country Status (6)

Country Link
US (1) US8962669B2 (enExample)
EP (1) EP2579847A1 (enExample)
JP (2) JP5832451B2 (enExample)
KR (1) KR101806304B1 (enExample)
CN (1) CN102933201B (enExample)
WO (1) WO2011155640A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10130610B2 (en) 2009-04-09 2018-11-20 Pola Pharma Inc. Antimycotic pharmaceutical composition
KR101409792B1 (ko) 2009-04-09 2014-06-19 니혼노야쿠가부시키가이샤 항진균성 약제학적 조성물
WO2011024620A1 (en) 2009-08-25 2011-03-03 Pola Pharma Inc. Antimycotic pharmaceutical composition
CN104105472A (zh) 2011-12-20 2014-10-15 维奥姆生物科学有限公司 用于治疗真菌感染的局部油组合物
CN103179634A (zh) * 2011-12-21 2013-06-26 株式会社Ntt都科摩 一种伙伴发现和选择方法、装置及系统
WO2014017411A1 (ja) * 2012-07-23 2014-01-30 マルホ株式会社 爪白癬治療用外用剤
US9199977B2 (en) 2012-09-14 2015-12-01 Pola Pharma Inc. Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal
RU2621615C2 (ru) * 2012-09-14 2017-06-06 Пола Фарма Инк. Фармацевтическая композиция, содержащая луликоназол
CN104619704B (zh) 2012-09-14 2017-12-05 宝丽制药股份有限公司 表面自由能用于分化评价晶体的用途，基于表面自由能作为指标评价的晶体，以及通过包含所述晶体制备的药物组合物
JP5460797B1 (ja) * 2012-09-14 2014-04-02 株式会社ポーラファルマ アミド誘導体及び安定性指標としてのその使用
CN104284662A (zh) 2012-09-14 2015-01-14 宝丽制药股份有限公司 晶体及包含该晶体的药物制剂
JP5589110B1 (ja) 2013-03-08 2014-09-10 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP2016518306A (ja) * 2013-05-17 2016-06-23 株式会社ポーラファルマ アスペルギルス、カンジダ等を病原体とする疾患用の医薬組成物
JP5680161B1 (ja) 2013-09-06 2015-03-04 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP5587488B1 (ja) 2013-12-12 2014-09-10 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質
CN107865825B (zh) * 2016-09-28 2022-05-20 四川海思科制药有限公司 一种卢立康唑外用喷雾剂药物组合物及其制备方法
CN108934161A (zh) * 2017-03-29 2018-12-04 日本农药株式会社 用于治疗感染症的医药组合物
US10898470B1 (en) 2019-08-13 2021-01-26 Sato Pharmaceutical Co., Ltd. Pharmaceutical composition containing antifungal agent as active ingredient
CN114981379B (zh) * 2019-10-08 2024-05-14 哈尔卢克斯股份有限公司 治疗甲癣的组合物和方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999039680A1 (en) * 1998-02-09 1999-08-12 Macrochem Corporation Antifungal nail lacquer and method using same
EP2025337A1 (en) * 2006-03-08 2009-02-18 Nihon Nohyaku Co., Ltd. External pharmaceutical composition
EP2191825A1 (en) * 2007-08-27 2010-06-02 Nihon Nohyaku CO., LTD. Agent for fungal dermatitis

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861764A (en) 1986-11-17 1989-08-29 Macro Chem. Corp. Percutaneous absorption enhancers, compositions containing same and method of use
JP3081766B2 (ja) 1994-05-06 2000-08-28 東興薬品工業株式会社 角質貯留型抗真菌外用組成物
JPH08245377A (ja) 1995-03-15 1996-09-24 Yamanouchi Pharmaceut Co Ltd 経皮吸収用製剤
EP0839035B1 (en) * 1995-07-08 2002-10-02 Nihon Nohyaku Co., Ltd. Antifungal agent, compound therefor, process for producing the same
JP3278738B2 (ja) 1995-07-08 2002-04-30 日本農薬株式会社 抗真菌剤
JP2002114680A (ja) * 2000-07-31 2002-04-16 Nippon Nohyaku Co Ltd 抗真菌剤
JP2002363070A (ja) * 2001-06-06 2002-12-18 Yuutoku Yakuhin Kogyo Kk 経皮吸収貼付剤
EA012599B1 (ru) * 2003-04-10 2009-10-30 Ньюроджескс, Инк. Способы и композиции для введения агонистов trpv1
JP2007102242A (ja) 2003-08-05 2007-04-19 Sumitomo Electric Ind Ltd 液晶パネル
CN101137369A (zh) * 2005-02-09 2008-03-05 马库赛特公司 用于眼治疗的制剂
JP2006306734A (ja) 2005-04-26 2006-11-09 Tsumura & Co 尿素配合外用剤
EP2005958B1 (en) * 2006-03-08 2013-04-17 Nihon Nohyaku Co., Ltd. External pharmaceutical composition
JP5184342B2 (ja) 2006-03-08 2013-04-17 日本農薬株式会社 外用の医薬組成物
JP4476991B2 (ja) 2006-11-28 2010-06-09 株式会社半導体エネルギー研究所 電気光学装置
CN101808638B (zh) 2007-09-05 2012-07-25 宝丽制药股份有限公司 抗真菌组合物
WO2009031642A1 (ja) * 2007-09-05 2009-03-12 Pola Pharma Inc. 医薬組成物
EP2191828B1 (en) 2007-09-05 2016-08-10 Pola Pharma Inc. Antifungal pharmaceutical composition
CN102395274B (zh) 2009-02-13 2014-03-12 托派卡医药股份有限公司 抗真菌制剂
KR101409792B1 (ko) * 2009-04-09 2014-06-19 니혼노야쿠가부시키가이샤 항진균성 약제학적 조성물
US10130610B2 (en) 2009-04-09 2018-11-20 Pola Pharma Inc. Antimycotic pharmaceutical composition
WO2011024620A1 (en) 2009-08-25 2011-03-03 Pola Pharma Inc. Antimycotic pharmaceutical composition
CN104284662A (zh) 2012-09-14 2015-01-14 宝丽制药股份有限公司 晶体及包含该晶体的药物制剂
CN104619704B (zh) 2012-09-14 2017-12-05 宝丽制药股份有限公司 表面自由能用于分化评价晶体的用途，基于表面自由能作为指标评价的晶体，以及通过包含所述晶体制备的药物组合物
US9199977B2 (en) 2012-09-14 2015-12-01 Pola Pharma Inc. Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal
RU2621615C2 (ru) 2012-09-14 2017-06-06 Пола Фарма Инк. Фармацевтическая композиция, содержащая луликоназол
JP5460797B1 (ja) 2012-09-14 2014-04-02 株式会社ポーラファルマ アミド誘導体及び安定性指標としてのその使用
JP5589110B1 (ja) 2013-03-08 2014-09-10 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999039680A1 (en) * 1998-02-09 1999-08-12 Macrochem Corporation Antifungal nail lacquer and method using same
EP2025337A1 (en) * 2006-03-08 2009-02-18 Nihon Nohyaku Co., Ltd. External pharmaceutical composition
EP2191825A1 (en) * 2007-08-27 2010-06-02 Nihon Nohyaku CO., LTD. Agent for fungal dermatitis

Also Published As

Publication number Publication date
US20130090365A1 (en) 2013-04-11
KR101806304B1 (ko) 2017-12-07
KR20130112727A (ko) 2013-10-14
US8962669B2 (en) 2015-02-24
JP5938497B2 (ja) 2016-06-22
JP5832451B2 (ja) 2015-12-16
WO2011155640A1 (en) 2011-12-15
CN102933201A (zh) 2013-02-13
JP2013528157A (ja) 2013-07-08
EP2579847A1 (en) 2013-04-17
JP2015163655A (ja) 2015-09-10

Similar Documents

Publication Publication Date Title
CN102933201B (zh) 抗真菌药物组合物
CN102481286B (zh) 抗真菌药物组合物
CN102387785B (zh) 抗真菌药物组合物
EP2459221B1 (fr) Formulation pharmaceutique
KR101590072B1 (ko) 두타스테라이드를 포함하는 자가유화 약물전달 시스템용 조성물
JP6356873B2 (ja) タキサン系活性成分含有液体組成物及び液体製剤
JP2011510001A (ja) イミキモド製剤
KR102871600B1 (ko) 항진균약을 유효성분으로 하는 의약 조성물
JP2009509942A (ja) フルベストラント製剤
TWI544924B (zh) 經皮吸收製劑
JP6292267B2 (ja) ドセタキセル製剤
AU2008250717A1 (en) Aqueous pharmaceutical preparation
JP2018530597A (ja) フルベストラント組成物
JP2013194009A (ja) ドセタキセル製剤
NL2028762B1 (en) Micelle-generating formulations for enhanced bioavailability
JP2003160489A (ja) オンダンセトロン経皮吸収用医薬組成物
JP2018115178A (ja) ドセタキセル製剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant